Project Grant HT94252410362
Award Date
7/1/24
Completion Date
6/30/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,229,872.00 to Baylor College of Medicine to study the clinical and genetic architecture of autism spectrum disorder among individuals with tuberous sclerosis complex. The award commenced on July 1, 2025 and is scheduled for completion on June 30, 2028. Baylor College of Medicine, a private non-profit university in Houston, Texas,...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $628,677 to the University of Texas at Austin to conduct research on "Brain Representations of Language in Children with Tuberous Sclerosis Complex." The purpose of this 3-year award, beginning on July 1, 2024, is to investigate neurocognitive processes related to language development in children with this genetic disorder. As a leading research...
This $802,500 Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports preclinical gene therapy studies in a mouse model of TSC2 at Baylor College of Medicine in Houston, Texas. The 3-year award period runs from May 1, 2025 to April 30, 2028 and aims to advance research on genetic disorders through innovative biomedical investigations. As a premier academic medical institution, Baylor...
The U.S. Department of Defense (DoD) awarded a $1,683,194 Project Grant through the Military Medical Research and Development (CFDA 12.420) program to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Incorporated) for a research project titled "ROLE OF THE GLYCOME IN TSC BIOMARKER IDENTIFICATION AND MOLECULAR PATHOGENESIS". The award period runs from August 1, 2025 to July 31, 2028. The grant supports advanced biomedical research focused on transforming...
This Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) provides $793,572.00 to Brigham & Womens Hospital Inc. for a research project titled "A NOVEL TRANSLATIONAL MECHANISM UNDERLYING TSC PATHOPHYSIOLOGY". The award period runs from August 15, 2024 to August 14, 2027. The project aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $148,942 to the Westfaelische Wilhelms-Universitaet Muenster in Germany to conduct research on identifying and characterizing the guanine nucleotide exchange factor (GEF) for the small GTPase Rheb as a novel target for treating tuberous sclerosis complex (TSC). The two-year award, running from July 1, 2024 to June 30, 2026, will support the university's...
The Children's Hospital Corporation, doing business as Boston Children's Hospital, was awarded a $796,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from July 2021 through June 2024 to investigate the contribution of rapamycin-insensitive processes to neurological symptoms in tuberous sclerosis complex. The Military Medical Research and Development program aims to advance biomedical...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,759,500.00 to Baylor College of Medicine in Houston, Texas to support research aimed at "Creating Cures for Patients with Langerhans Cell Histiocytosis." The award, which runs from September 1, 2024 to August 31, 2028, will enable Baylor to conduct innovative biomedical studies to develop new treatments and therapies for this rare genetic...
This Project Grant award, valued at $822,501.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, entitled "RESTORING GABAERGIC INHIBITION AS A POTENTIAL THERAPY FOR TSC-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT," aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public. The grant, awarded to The Trustees of Columbia University...
The Washington University received a $236,250 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant funding supports research from July 1, 2021 to June 30, 2023 to study the role of blood-brain barrier dysfunction in epilepsy associated with tuberous sclerosis complex. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...